Ixekizumab, a promising agent for psoriatic arthritis
According to recent research, approximately one-third of patients on a new psoriasis drug had clear skin after three months on medication. The IL-17A inhibitor, ixekizumab appears to be dramatically effective in psoriatic arthritis. Ixekizumab targets interleukin 17A (IL-17A), which is a cytokine involved in inflammation.
Phase 3 data from the SPIRIT-P1 study showed ixekizumab as safe and effective in psoriatic arthritis (PsA) patients who have not previously been treated with biological disease-modifying anti-rheumatic drugs (bDMARDs).
Psoriasis affects between 2 to 4% of the population, and occurs by abnormal production of skin cells, causing red skin patches. In addition to itchy skin, psoriasis is linked to increased risk of depression, arthritis, lymphomas, cardiovascular disease and diabetes. Several treatment options are available to relieve and reduce psoriasis complications. Ixekizumab is among those. Study enrolled patients with psoriatic arthritis and who were not treated with biologics, such as tumor necrosis factor alpha inhibitors. Thus, researchers warn that the findings might not be generalizable to patients who have failed prior biologic therapy.
In this study, patients were treated with either 80 mg of ixekizumab once every two weeks or every four weeks (following 160 mg starting dose); adalimumab at 40 mg every other week; or placebo. Adalimumab was the active control in SPIRIT-P1 study. In both dosing regimens, ixekizumab-treated patients demonstrated significant improvements than placebo in disease activity of PsA. Improvements were experienced as early as one week after treatment initiation. Other measures included ACR50 and ACR70, which represent 50% and 70% reductions in disease activity.
Ixekizumab has been approved by U.S. Food and Drug Administration for use in moderate to severe psoriatic arthritis. In conclusion, Ixekizumab significantly helped signs and symptoms of psoriatic arthritis in a phase 3 study.